BioLineRx Ltd Market Cap ($9.50 Million)
Market Cap & Net Worth: BioLineRx Ltd (BLRX)
BioLineRx Ltd market cap. BioLineRx Ltd (NASDAQ:BLRX) has a market capitalization of $9.50 Million ($9.50 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27071 globally and #5627 in its home market, demonstrating a -3.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioLineRx Ltd's stock price $1.96 by its total outstanding shares 4848991 (4.85 Million). Also see BLRX cash flow metrics for how efficiently the company converts equity into cash flow.
BioLineRx Ltd Market Cap History (2015–2026)
BioLineRx Ltd market cap history from 2015 to 2026. Data shows change from $94.56 Million to $9.50 Million (-20.06% CAGR). Check BLRX live share price for real-time trading data and today's change.
Index Memberships
BioLineRx Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #758 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2474 of 3165 |
Weight: BioLineRx Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioLineRx Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioLineRx Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BioLineRx Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.29x
BioLineRx Ltd's market cap is 11.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $7.61 Million | $4.80 Million | -$60.61 Million | 1.59x | N/A |
| 2024 | $1.04 Million | $28.94 Million | -$9.22 Million | 0.04x | N/A |
| 2025 | $13.43 Million | $1.19 Million | -$1.18 Million | 11.29x | N/A |
Competitor Companies of BLRX by Market Capitalization
Companies near BioLineRx Ltd in the global market cap rankings as of November 4, 2026. Also see BLRX asset base for a full breakdown of the balance sheet.
Key companies related to BioLineRx Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of BioLineRx Ltd (2015–2026)
Market capitalization of BioLineRx Ltd from 2015 to today. Between 2015 and today, BioLineRx Ltd's market cap moved from $94.56 Million to $ 9.50 Million, with a yearly change of -20.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.50 Million | -29.24% |
| 2025 | $13.43 Million | +1194.39% |
| 2024 | $1.04 Million | -86.37% |
| 2023 | $7.61 Million | +166.10% |
| 2022 | $2.86 Million | -71.08% |
| 2021 | $9.89 Million | -19.05% |
| 2020 | $12.22 Million | +12.00% |
| 2019 | $10.91 Million | -65.70% |
| 2018 | $31.81 Million | -59.88% |
| 2017 | $79.28 Million | +18.48% |
| 2016 | $66.92 Million | -29.23% |
| 2015 | $94.56 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of BioLineRx Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.50 Million USD |
| MoneyControl | $9.50 Million USD |
| MarketWatch | $9.50 Million USD |
| marketcap.company | $9.50 Million USD |
| Reuters | $9.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more